---
title: Dermatosis Papulosa Nigra
nct_id: NCT00710203
overall_status: COMPLETED
phase: NA
sponsor: University of California, Davis
study_type: INTERVENTIONAL
primary_condition: Facial Dermatoses
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00710203.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00710203"
ct_last_update_post_date: 2015-04-28
last_seen_at: "2026-05-12T06:16:32.785Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Dermatosis Papulosa Nigra

**Official Title:** Efficacy of a 585 nm Pulsed Dye Laser (PDL) for the Treatment of Dermatosis Papulosa Nigra, and Compare it to Therapy With Curettage and Electrodesiccation.

**NCT ID:** [NCT00710203](https://clinicaltrials.gov/study/NCT00710203)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 10
- **Lead Sponsor:** University of California, Davis
- **Conditions:** Facial Dermatoses, Seborrheic Keratoses
- **Start Date:** 2008-07
- **Completion Date:** 2009-12
- **CT.gov Last Update:** 2015-04-28

## Brief Summary

DPN is a disorder among darkly pigmented patients, manifested by small, benign, variants of seborrheic keratoses, predominantly on the face.

The purpose of this study is to determine the efficacy of a 585 nm PDL for the treatment of Dermatosis Papulosa Nigra, and compare it to therapy with curettage (scraping the lesions off) and electrodesiccation (burning the lesions off).

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Over 18 years of age.
* Able to give informed consent.
* Desires removal of lesions.
* Willing to come back for six week follow-up.
* Willing to fill out post operative questionnaire.
* At least 4 lesions less than 7 mm.
* Diagnosis of Dermatosis Papulosa Nigra (DPN)

Exclusion Criteria:

* Less than 18 years of age.
* Pregnant.
* Sensitive to laser energy.
* History of Collagen Vascular Disorders.
* History of Keloids.
* History of post inflammatory hyperpigmentation.
* Incarcerated.
* Unable to give informed consent.
* Unable to follow up for post operative evaluation.
* Unable to complete patient visual analogue scale.
* Unable to understand consent process or risks.
* Unable to accept risk of scar, infection, minor bleeding, permanent or prolonged hyperpigmentation and hypopigmentation.
```

## Arms

- **Pulsed dye laser** (ACTIVE_COMPARATOR) — Four lesions are selected on each subject for study. One lesion will be chosen for treatment with the pulsed dye laser with a 7 mm spot size. A single 10 J/cm2 pulse with 10 ms pulse duration will be used to treat the lesion.
- **Curettage** (ACTIVE_COMPARATOR) — Four lesions are selected on each subject for study. A second lesion will be treated with curettage with or without anesthetic, depending on the patient's preference.
- **Electrodesiccation** (ACTIVE_COMPARATOR) — Four lesions are selected on each subject for study. A third lesion will be treated with electrodesiccation after infiltration of 1% lidocaine with epinephrine.
- **No treatment** (ACTIVE_COMPARATOR) — Four lesions are selected on each subject for study. A fourth lesion will not be treated and will serve as a control.

## Interventions

- **Pulsed dye laser** (DEVICE) — One lesion will be chosen for treatment with the pulsed dye laser with a 7 mm spot size. A single 10 J/cm2 pulse with 10 ms pulse duration will be used to treat the lesion.
- **Curettage** (PROCEDURE) — A second lesion will be treated with curettage with or without anesthetic, depending on the patient's preference.
- **Electrodesiccation** (PROCEDURE) — A third lesion will be treated with electrodesiccation after infiltration of 1% lidocaine with epinephrine.
- **No treatment** (OTHER) — A fourth lesion will not be treated and will serve as a control.

## Primary Outcomes

- **Percent Clearance of All Lesions** _(time frame: 6 to 12 weeks)_ — The physician assessed percent clearance of all treated lesions and the control lesion.

## Locations (1)

- University of California, Davis Department of Dermatology, Sacramento, California, United States

## Recent Field Changes (last 30 days)

- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `locations.university of california, davis department of dermatology|sacramento|california|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00710203.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00710203*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*